6-Feb-2026
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR
Business Wire (Wed, 28-Jan 7:00 AM ET)
Business Wire (Tue, 20-Jan 7:00 AM ET)
Business Wire (Tue, 13-Jan 4:05 PM ET)
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Business Wire (Tue, 16-Dec 7:00 AM ET)
Glaukos Reports Record Sales and Improved Margins: Revenue Guidance Raised for 2025 and 2026
Market Chameleon (Thu, 30-Oct 6:33 AM ET)
Market Chameleon (Mon, 20-Oct 4:44 AM ET)
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of February 6, 2026, GKOS stock price declined to $112.52 with 890,449 million shares trading.
GKOS has a beta of 1.37, meaning it tends to be more sensitive to market movements. GKOS has a correlation of 0.20 to the broad based SPY ETF.
GKOS has a market cap of $6.45 billion. This is considered a Mid Cap stock.
Last quarter Glaukos reported $134 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.10.
In the last 3 years, GKOS traded as high as $163.71 and as low as $44.26.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
GKOS has underperformed the market in the last year with a price return of -27.5% while the SPY ETF gained +15.1%. However, in the short term, GKOS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +37.6% vs +3.3% return in SPY. But in the last 2 weeks, GKOS shares have been beat by the market, returning -6.2% compared to an SPY return of +0.2%.
GKOS support price is $109.09 and resistance is $117.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS shares will trade within this expected range on the day.